Among the 356,222 men screened for the Multiple Risk Factor Intervention Trial who had no history of hospitalization for heart attack at entry, more than 2,000 coronary deaths occurred during 6 years of follow-up. With this large data set, detailed cross-tabulations clearly and simply showed the strong graded relation between blood pressure and coronary heart disease death. This risk gradient was evident in each of five age groups ranging from 35 to 57 years and for levels of diastolic blood pressure ranging from less than 75 mm Hg to greater than 115 mm Hg. Systolic blood pressure was more strongly associated with coronary heart disease death than was diastolic blood pressure, and isolated systolic blood pressure elevation was found to be an important risk factor in these middle-aged men. The risk of coronary death was increased among hypertensive men who had elevated serum cholesterol levels or who smoked cigarettes. Because less than 10% of hypertensive men had cholesterol levels in the lowest quintile (below 182 mg/dl) and were nonsmokers, a multi-intervention approach for the large majority of hypertensive persons is clearly indicated. Risks of death were also substantially increased among those hypertensive men who already had end-organ damage, emphasizing the importance of early treatment to prevent such damage. These findings have implications for the design of prevention trials and clinical practice, as it is clear that systolic as well as diastolic blood pressure should be considered in treating hypertensive patients. Additionally, treatment goals should be directed at preventing not only death but many other morbid events, clinical and subclinical, that are associated with elevated blood pressure and that are preventable with appropriate treatment. {Hypertension 1989;13(suppl I):I-2-1-12) M any available data sets delineate the role of elevated blood pressure (BP) as a major, etiologically significant, established risk factor for coronary heart disease (CHD). '-9 This report documents this relation further by drawing primarily on the findings that have recently become available for the 361,662 men screened in the recruitment effort of the Multiple Risk Factor Intervention Trial (MRFIT). i°-'6 Advantage is taken of the large size of this sample and the standardized collection of BP data to explore in detail the relation of systolic BP (SBP) and diastolic BP (DBP) to the risk of CHD death. The influences of SBP and of DBP on age-specific CHD risk are described, considered separately, and then considered in combination. 
M
any available data sets delineate the role of elevated blood pressure (BP) as a major, etiologically significant, established risk factor for coronary heart disease (CHD). '-9 This report documents this relation further by drawing primarily on the findings that have recently become available for the 361,662 men screened in the recruitment effort of the Multiple Risk Factor Intervention Trial (MRFIT). i°-'6 Advantage is taken of the large size of this sample and the standardized collection of BP data to explore in detail the relation of systolic BP (SBP) and diastolic BP (DBP) to the risk of CHD death. The influences of SBP and of DBP on age-specific CHD risk are described, considered separately, and then considered in combination. MRFIT, Multiple Risk Factor Intervention Trial. *Coronary heart disease mortality is reported as age-specific rates (per 1,000 men) or as age-standardized rates for all 356,222 men aged 35-57 years with no history of hospitalization for myocardial infarction on entry into the MRFIT study.
tNumber of deaths. *Number of men. §Death rate per 1,000 men. Rates in parentheses are based on <10 deaths for that stratum. Coronary heart disease is based on codes 410-414 of the International Classification ofDiseases." 1 Ascertainment is estimated to be 88% complete. 17 Six-year CHD mortality data (ICD 9 codes 410-414) are given in this report for men aged 35-39,40-44, 45-49, 50-54, and 55-57 years at screening, as well as age-standardized data for the entire cohort.
Diastolic Blood Pressure, Systolic Blood Pressure, and Coronary Heart Disease Mortality in MRFIT Men
Findings on the relation of BP to risk of CHD death were similar for white and black men in the MRFIT cohort," hence the data presented here are for the entire cohort. Tables 1 and 2 give detailed data on 6-year risk of CHD death by baseline DBP and baseline SBP, respectively, with BP grouped into 5 mm Hg intervals. For each 5-year age group, the CHD mortality rate increased progressively with higher DBP and SBP. Relative risks, that is, ratios of 6-year CHD mortality rates for men with the highest BP compared with men with the lowest BP, were all large, ranging from 4.3 to 7.6 (with exclusion of those values based on <10 CHD deaths). For men with DBP in the range 85-89 mm Hg, the age-specific risks relative to men with DBP less than 75 mm Hg ranged from 1.51 to 1.83; for men with SBP in the range 130-134 mm Hg compared with those with SBP less than 115 mm Hg, relative risks ranged from 1.48 to 2.75. Two thirds of these men had DBP levels greater than or equal to 80 mm Hg at baseline; 44%, with DBP greater than or equal to 85 mm Hg; 60%, with SBP levels greater than or equal to 125 mm Hg; and 46%, with SBP levels greater than or equal to 130 mm Hg. Thus, in a majority of men aged 35-57 years, BP levels were found to be significantly above optimal. If the lowest levels of DBP and SBP, that is, DBP less than 75 mm Hg and SBP less than 115 mm Hg, are designated optimal, then based on DBP and SBP, 35% and 46%, respectively, of CHD deaths were excess deaths attributable to BP levels above optimal.
These data give a precise estimate of the real scope of the BP problem among US adults. This problem is not limited to the substantial minority of people with BP levels in the hypertensive range, which is generally defined for clinical purposes as a mean DBP greater than or equal to 90 mm Hg or a mean SBP of greater than or equal to 140 mm Hg.
The data on relative risk in Tables 1 and 2 suggest that, at least at ages 45 years and above, there is a stronger association of SBP with CHD risk than there is with DBP and CHD risk. This matter is addressed further in the following section.
Quintiles of Diastolic Blood Pressure, Systolic Blood Pressure, and Coronary Heart Disease Risk in MRFIT Men
To facilitate comparisons of DBP and SBP distributions, quintile analyses were performed. Table 3 presents data on quintiles of DBP and SBP and on age-specific and age-adjusted 6-year CHD death rates. The tabulation includes relative risks of 6-year CHD death for Quintile 5 compared with Quintile 1 of DBP and SBP. With DBP and SBP, These data also underscore the soundness of the recommendation by the National High Blood Pressure Education Program and its Advisory Committee that a DBP of 85-89 mm Hg be designated as high-normal. Clearly, the same designation is appropriate for the 130-139 mm Hg SBP stratum. Further, these data support the judgment that the term "borderline" for the 90-94 mm Hg DBP stratum and the 140-159 mm Hg SBP stratum is archaic and should be abandoned. Adults aged 30 years and older with such average blood pressure measurements from multiple readings are properly diagnosed as hypertensive, and, given their increased risks, the designation "mild" for the 90-104 mm Hg DBP stratum is also archaic.
Diastolic Blood Pressure Greater Than or Equal to 85 mm Hg, Systolic Blood Pressure Greater Than or Equal to 130 mm Hg, and Coronary Heart Disease Risk in MRFIT Men
The cut points, SBP greater than or equal to 130 mm Hg and DBP greater than or equal to 85 mm Hg, divide the MRFIT cohort approximately in half as noted above. Table 4 summarizes the age-specific risks of 6-year CHD death for MRFIT men with DBP greater than or equal to 85 mm Hg and with SBP greater than or equal to 130 mm Hg. Relative risks, that is, the ratios DBPs85/DBP<85 and SBP>130/SBP<130 were higher in men with SBP greater than or equal to 130 than in men with DBP greater than or equal to 85 from ages 45-49 years and older.
Also, absolute excess risks, that is, the differences in 6-year CHD mortality rates between men with higher and lower BP, were from age 45-49 years and older greater in men with SBP greater MRFIT, Multiple Risk Factor Intervention Trial; BP, blood pressure; DBP, diastolic blood pressure; and SBP, systolic blood pressure. *Coronary heart disease mortality is reported as age-specific rates (per 1,000 men) or as age-standardized rates for all 347,935 men aged 35-57 years with no history of hospitalization for myocardial infarction on entry into the MRFIT study, tAge-adjusted rates.
than or equal to 130 mm Hg than in those with DBP greater than or equal to 85 mm Hg. Relative risks associated with elevated DBP tended to be lower in older men; absolute excess risks were progressively higher with increasing age based on either the SBP or the DBP cut point. Further, excess CHD deaths as a percentage of all CHD deaths for each age group were greater with SBP greater than or equal to 130 mm Hg than with DBP greater than or equal to 85 mm Hg. The numbers of excess CHD deaths per 100,000 population in 6 years were substantial. As can readily be calculated from Tables 1 and 2 , most of these excess deaths came from the large strata with BP only "moderately" elevated (i.e., DBP in the range 85-104 mm Hg or SBP in the range 130-159 mm Hg). These are the strata where "the action is" regarding the reduction of the impact of the BP problem on CHD in the United States. Of course, severe elevations of DBP and SBP are a serious problem clinically, but their prevalence rates are relatively low nowadays, and hence, their control can make only a small contribution to further reducing the great toll of CHD attributable to above-optimal BP levels.
Blood Pressure and Coronary Heart Disease Risk in Women
The problem as summarized for men is similar for white and black women. No data set like MRFIT, with standardized BP measurements for a cohort of several hundred thousand persons, is available for women. Table 5 is representative of data extant for US women; these data include 9-year follow-up information for almost 9,000 white women in the Chicago Heart Association Detection Project in Industry study. 19 Risks of death from CHD, from all cardiovascular diseases, and from all causes were markedly increased for women with DBP in the range 90-104 mm Hg, and greater than or equal to 105 mm Hg. Again, most of the excess deaths attributable to elevated DBP were from the large 90-104 mm Hg stratum. Although the numbers of deaths were small, the data suggest that CHD risk was also increased among women with DBP in the range 80-89 mm Hg compared with those with DBP less than 80 mm Hg, as was clearly the case for the MRFIT men. More data for women are needed on this matter. 
Influence of Systolic Blood Pressure on Coronary Heart Disease Risk for Men With Elevated Diastolic Blood Pressure, MRFIT Men
In the tabulations presented up to this point, DBP and SBP were considered separately. Based on the data for the large MRFIT primary screenee cohort, the conclusion is warranted that, for men aged 45-49 years and above but not for younger men, SBP is a better indicator of CHD risk than is DBP. Data from other prospective population studies lend support to this conclusion. Table 6 summarizes the key findings. At each level of DBP, the higher the SBP, the greater the agestandardized 6-year CHD death rate. Note also the unexpected finding: for men within each category of SBP above 130 mm Hg, there does not seem to be a consistent graded relation between DBP and CHD risk. Differential treatment during follow-up may partly explain the similarity of the rates for these DBP groups; however, data on the use of antihypertensive treatment at baseline and during followup were not collected.
Clearly, the massive MRFIT data show that SBP is important. It is a better discriminator of CHD risk than is DBP for men aged 45-49 years and older, and, for men in each 5 mm Hg category of elevated DBP, SBP gives additional information about CHD risk. For all those investigators who have been focusing almost exclusively on DBP, these data must be regarded as extremely revealing about the need for concern about SBP in epidemiological research, in the design of clinical trials, and in the practice of clinical medicine and public health.
Isolated Systolic Blood Pressure Elevation in Middle-Aged MRFIT Men
In recent years, much attention has been given to the impact of isolated systolic hypertension (ISH) 26 Until recently, 16 little attention has been paid to the matter of ISH in middle-aged persons. Again, the massive MRFIT data set gives a revealing insight (Table 7) . For men with DBP in the ranges 70-74, 75-79, and 80-84 mm Hg at baseline, SBP in the range 130-139 and greater was tRates were adjusted by the direct method for distributional differences in age, sex, and race; common standard population was all HDFP participants.
tMajor end-organ damage at entry is defined as evidence of probable myocardial infarction, stroke, definite left ventricular hypertrophy on electrocardiogram, intermittent claudication, or serum creatininea 1.7 mg/dl.
Reprinted with permission from Progress in Cardiovascular Diseases (l986;29(suppl):3-10), Copyright © 1986, Grune & Stratton, Incorporated. associated with higher CHD death rates than for men with SBP less than 130 mm Hg. Once again, the data indicate the relevance of SBP. This particular problem, ISH in younger adults, needs to be given attention. Why are there increased risks, and what can be done safely about them?
Impact of Other Risk Factors on Prognosis of People With High Blood Pressure
To this point, this presentation has dealt only with BP and CHD risk. It is well established that the CHD epidemic has multiple causes. Other major risk factors like serum cholesterol levels and cigarette smoking markedly influence the CHD risk of people with high BP as well as those with normal BP. 1 -9 The massive data on the MRF1T primary screenees add new documentation to these previously demonstrated phenomena. As Table 8 shows, for men with high DBP (>90 mm Hg), for nonsmokers and smokers alike, the higher the serum cholesterol level, the higher the risk of CHD death. 15 The additional increments in risk for hypertensive men with even "moderate" elevations of serum cholesterol were substantial, for example, a 6-year CHD death rate of 9.2/1,000 for all hypertensive men with serum cholesterol in the range 221-244 mg/dl (Quintile 4) versus 4.6/1,000 for hypertensive men with serum cholesterol less than 182 mg/dl (Quintile 1), that is, a further doubling of risk. Further, at any level of serum cholesterol, hypertensive men who were smokers were at much greater risk by 2.4 times overall than were hypertensive nonsmokers.
These findings are concordant with those from many studies.
1 -818 - 27 The implications of these data for the management of people with high BP are clear: as much as can be done for them by controlling their blood pressure, if their smoking status and serum cholesterol levels are neglected, one is fighting the battle for improved prognosis with one arm tied behind the back. Note in Table 8 that less than 10% of the hypertensive men, 9,612 of 100,032, were nonsmokers with optimal serum cholesterol levels of less than 182 mg/dl. Most hypertensive persons need counseling regarding the multiple aspects of lifestyle for control of the multiple risk factors influencing their prognosis. The data on the MRFIT men further show that, all else being equal, hypertensive men with a history of treatment for clinical diabetes have a 6-year risk of fatal CHD almost three times greater than nondiabetic hypertensive men. Most of these diabetic men almost certainly had non-insulin-dependent diabetes for which the key known risk factor is marked overweight. Overweight is also a key risk factor for high BP (along with high salt intake and excess alcohol consumption). Further, among the US and other populations habitually consuming a diet high in saturated fat and cholesterol, overweight adds significantly to the risk of hypercholesterolemia. With all these nutritional considerations and the direct independent effect of "rich" diet on CHD risk, 9 the eating patterns of the tens of millions with hypertension must be of major concern, along with their smoking habits.
The situation is essentially the same for hypertensive women as it is for hypertensive men. 18 Three quarters of the women in the Chicago Heart Association Detection Project in Industry cohort with DBP from 90 to 104 mm Hg had one or more other risk factors; one quarter had an abnormal electrocardiogram. Risks of 9-year death from CHD, from all cardiovascular diseases, and from all causes were markedly increased for these women with DBP in the range 90-104 mm Hg who also had one or more of the other risk factors. Also, the prognosis for those with DBP in the range 90-104 mm Hg and an abnormal electrocardiogram compared with those with a normal electrocardiogram was much more unfavorable. 18 This last finding (again, one which is representative of data from many population studies on men and women, whites and blacks) documents a further key strategic consideration, the importance of detecting and controlling high BP early before end-organ damage has occurred, to prevent that damage, and to prevent people from developing this higher plane of risk.
Data from other trials further document the foregoing inferences as illustrated by the findings of the Hypertension Detection and Follow-up Program (HDFP) ( Table 9) . 28 For all participants and for those with DBP 90-104 mm Hg not taking antihypertensive drugs at entry, the 5-year mortality for smokers in the stepped-care (SC) and referred-care (RC) groups was much higher than that for nonsmokers. (Neither SC nor RC treatment addressed the smoking problem.) The intensive SC drug treatment program for hypertension led to a lower mortality rate for SC nonsmokers and SC smokers compared with the corresponding RC subgroup, but the intensive SC could not overcome the added risk of cigarette use in the absence of a systematic effort to achieve smoking cessation. Similar results were recorded by the British Medical Research Council Trial.
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Regarding the impaired prognosis for persons with high BP who have end-organ damage, the HDFP data also demonstrate this forcefully. Even with highly effective drug treatment to achieve and maintain BP normalization, 5-year mortality was about three times greater for SC participants with major end-organ damage at entry than it was for those without such damage (Table 9) . 28 This finding for people with DBP 90-104 mm Hg and not on drug treatment at entry prevailed for the 90-94, 95-99, and 100-104 mm Hg substrata. This finding underscores the soundness of the position adopted at the recent Kronberg Conference of the International Society of Hypertension and the World Health Organization; no one with end-organ damage, regardless of DBP, should be designated a "mild" hypertensive. 31 If the word "mild" is to be used at all, it should be reserved only for people with DBP 90-104 mm Hg (or 90-99 mm Hg) not on drug treatment (so that the reading is a true one) and without signs of end-organ damage. 
Blood Pressure and Nonfatal Plus Fatal Cardiac Events
So far, this report has dealt only with BP and CHD mortality, and there are too many papers in the recent literature giving the false impression that mortality is the only consideration. Data from many research studies illustrate this vividly. The data in Table 14 of the US Public Health Service (USPHS) Hospitals Trial and in Figure 1 of the HDFP are representative. The USPHS Hospitals Trial involved younger people (average age of 44 years compared with 51 years for the HDFP participants) without end-organ damage at baseline and with so-called mild hypertension. 33 As Table 10 shows, few deaths occurred during the 7-10 years of follow-up of the USPHS Hospital Trial participants. However, despite their age, their mild BP elevations, and their freedom from end-organ damage at baseline, morbid events were numerous: 160 in the placebo group in nearly one half the participants. Most of these were cardiac events, some clinical, some subclinical. All these events shifted these people to a new higher more-or-less irreversible plane of risk. Clearly, this is not a problem properly called mild. It is also obvious that any argument for deferring treatment based on the relatively low-order shortterm risk of death for such younger hypertensive individuals ignores the harsh reality of the greatly increased long-term risk of death for such persons if left untreated (e.g., by age 65) and the toll exacted by nonfatal events.
The 5-year follow-up data of the HDFP reinforce these conclusions. As shown in Figure 1 , almost one quarter of RC participants with DBP in the range 90-104 mm Hg and not taking medication at entry experienced a major nonfatal or fatal event in 5 years. 28 There were nearly twice as many major nonfatal as fatal events, and these do not include such meaningful incidents as other electrocardiographic abnormalities, cardiomegaly on chest x-ray, congestive heart failure, renal insufficiency, arterial insufficiency, retinopathy, and severe hypertension.
Note in Table 10 and Figure 1 the significant reduction in the incidence of combined nonfatal and fatal events with intensive sustained antihypertensive treatment, including the incidence of cardiac events. These combined end points are similar to the one used as the primary end point in the landmark Veterans Administration trial whose results ended the era of therapeutic nihilism and "judicious neglect" of high BP. For every trial reporting these data for such a combined end point, the outcome was favorable for the intensive-treatment group for this end point. This result also occurred for this end point in those trials with sample sizes too small to have had reasonable statistical power to minimize the likelihood of a false-negative finding for such end points as all-cause death, coronary death, or nonfatal myocardial infarction plus coronary death. The consistent results from many trials on the efficacy of intensive treatment against cardiac and cardiovascular disease events further emphasizes the wisdom of early and comprehensive treatment of all hypertensive individuals.
Summary
The following points should be noted: 1) Regarding the important role of BP as a major coronary risk factor, the BP problem is one involving the majority of adults aged 35 years and older in the US population. The BP problem encompasses but is not limited to those classed as hypertensive by the usual criteria (mean DBP > 90 mm Hg) and those currently called high-normal based on a DBP of 85-89 mm Hg. 2) For men aged 45-49 years and older, SBP is more strongly associated with risk of CHD than is DBP. 3) For persons with frankly elevated DBP (> 90 mm Hg) at any level of DBP, SBP gives additional information on risk. 4) For persons with DBP less than 85 mm Hg, including middle-aged individuals (as well as the elderly), risk is a function of SBP. 5) For persons with elevated BP, risk is increased by the presence of other risk factors, for example, serum cholesterol levels above optimal (i.e., s 180 mg/dl), smoking, diabetes, and "rich" diet. 6) For persons with elevated BP, risk is also increased for those with end-organ damage. 7) For persons with elevated BP, risks include not only death but also many additional morbid events, clinical and subclinical, producing sickness, disability, or impairment of prognosis. 8) The extensive data base on the BP problem serves as the foundation for comprehensive treatment strategy, pharmacological and nonpharmacological, that is essential for prevention and control of elevated BP. 34 -
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